Skip to main content
MSLE
NASDAQ Life Sciences

Satellos Completes BASECAMP Phase 2 Enrollment, Delays Topline Data to Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$8.6
Mkt Cap
$182.461M
52W Low
$5.44
52W High
$144
52W Position info
58% above low
Off High info
94% below high
Rel. Volume info
7.6× avg
Market data snapshot near publication time

MSLE sits 58% above its 52-week low of $5.44 on elevated volume (7.6× avg).

Summary

Satellos completed enrollment in its BASECAMP Phase 2 DMD trial ahead of schedule but delayed topline data to Q1 2027 to build a more complete dataset for potential FDA accelerated approval discussions.


Key Events · Product Development and Regulatory · MSLE

  • BASECAMP Enrollment Completed

    Enrollment surpassed target in under nine months across 18 sites in the U.S., Canada, Australia, Belgium, Spain, Poland, and Serbia.

  • Topline Data Delayed to Q1 2027

    Company adjusted its prior data-release plan, now targeting Q1 2027 to compile the most complete dataset for potential FDA accelerated approval discussions.

  • Trial Design Details

    Participants randomized 1:1:1 to forazapadin 60 mg, 120 mg, or placebo; 12-week placebo-controlled period followed by 36-week active treatment.

  • Accelerated Pathway Ambition

    Management believes BASECAMP could support FDA discussions on an accelerated development pathway for forazapadin in DMD.


Analysis · MSLE · Life Sciences

Satellos finished enrolling its pivotal BASECAMP Phase 2 trial for forazapadin in Duchenne muscular dystrophy, exceeding its target in under nine months. The company also pushed topline data from a previously implied earlier timeline to Q1 2027, citing a desire to compile the most complete dataset for potential FDA accelerated approval discussions. The delay is a modest negative — investors now wait longer for the key readout — but the rapid enrollment and explicit accelerated-pathway language keep the overall story constructive.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MSLE was trading at $8.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.5M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MSLE - Latest Insights

MSLE
Nov 12, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.88
Real-time Price: $6.44 info
Change: -$0.440 (-6%) info
Market Cap: $136.634M info
MSLE
Nov 06, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.00
Real-time Price: $6.44 info
Change: +$0.440 (+7%) info
Market Cap: $136.634M info
MSLE
Sep 24, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.91
Real-time Price: $6.44 info
Change: -$2.47 (-28%) info
Market Cap: $136.634M info
MSLE
Aug 13, 2026, 5:03 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.82
Real-time Price: $6.44 info
Change: -$3.38 (-34%) info
Market Cap: $136.634M info
MSLE
Jul 08, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.37
Real-time Price: $6.44 info
Change: -$1.93 (-23%) info
Market Cap: $136.634M info